- Home
- ARVN
ARVN
Arvinas Inc.
as 11-21-2024 11:31am EST
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | NEW HAVEN |
| Market Cap: | 1.7B | IPO Year: | 2018 |
| Target Price: | $61.08 | AVG Volume (30 days): | 702.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.46 | EPS Growth: | N/A |
| 52 Week Low/High: | $20.99 - $53.08 | Next Earning Date: | 10-30-2024 |
| Revenue: | $161,100,000 | Revenue Growth: | 1.07% |
| Revenue Growth (this year): | 237.44% | Revenue Growth (next year): | -20.28% |
Latest Arvinas Inc. News
ARVN Breaking Stock News: Dive into ARVN Ticker-Specific Updates for Smart Investing
Insider Monkey
2 days ago
Arvinas, Inc. (ARVN): This Small-Cap Stock Is Ready To Explode
GlobeNewswire
17 days ago
Arvinas to Participate in Upcoming Investor Conferences
Simply Wall St.
20 days ago
Arvinas Third Quarter 2024 Earnings: Beats Expectations
MT Newswires
21 days ago
UBS Adjusts Price Target on Arvinas to $74 From $82, Maintains Buy Rating
GuruFocus.com
21 days ago
Arvinas Inc (ARVN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Promising ...
MT Newswires
22 days ago
Arvinas' Q3 Net Loss Narrows, Revenue Rises
Zacks
22 days ago
Arvinas, Inc. (ARVN) Reports Q3 Loss, Tops Revenue Estimates
GlobeNewswire
22 days ago
Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Compare ARVN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ARVN Arvinas Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.